The two receptor targeting property, potent antitumor efficacy and its much smaller molecular size, suggested that EGF-IGF-LDP-AE would be a promising candidate for NSCLC targeted therapy. The gene discussed is IGF1; the disease is non-small cell lung carcinoma.